NCT00034541View on ClinicalTrials.gov

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

May 31, 2003

Study Completion Date

May 31, 2003

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIOLOGICAL

cetuximab

400 mg/m2 i.v. over 120 minutes

DRUG

paclitaxel

225 mg/m2, infusion

DRUG

carboplatin

30-minute AUC = 6, infusion.

Trial Locations (3)

46202

ImClone Investigational Site, Indianapolis

80262

ImClone Investigational Site, Denver

06830

ImClone Investigational Site, Greenwich

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

collaborator

Greenwich Hospital

OTHER

collaborator

Indiana University

OTHER

lead

Eli Lilly and Company

INDUSTRY

NCT00034541 - Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter